Literature DB >> 12544834

Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders.

Gabor G Kovacs1, Stefan Klöppel, Ingeborg Fischer, Suzanne Dorner, Elisabeth Lindeck-Pozza, Peter Birner, Ingolf C Bötefür, Peter Pilz, Benedikt Volk, Herbert Budka.   

Abstract

Neurodegenerative diseases share symptoms suggested to be related to the serotonergic system. To evaluate the involvement of serotonergic raphe nuclei, we compared the percentage of neurons synthesizing serotonin in the nucleus centralis superior (NCS), raphe obscurus and pallidus (NROP) in Alzheimer's disease (AD), progressive supranuclear palsy (PSP), Parkinson's disease (PD), multiple system atrophy (MSA), and control brains. We used immunohistochemistry for tryptophan hydroxylase (TpOH), phosphorylated tau, and alpha-synuclein. We observed a significant decrease in the NCS in the NROP in AD, but a significant increase in PSP and MSA. Cytoskeletal pathology was present in the NCS and NROP to a variable degree. We conclude that there is disease- and nucleus-specific alteration of serotonin synthesis in the raphe. Copyright 2003 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12544834     DOI: 10.1097/00001756-200301200-00014

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  18 in total

1.  Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter.

Authors:  Karl Strecker; Florian Wegner; Swen Hesse; Georg-Alexander Becker; Marianne Patt; Philipp M Meyer; Donald Lobsien; Johannes Schwarz; Osama Sabri
Journal:  J Neurol       Date:  2010-07-21       Impact factor: 4.849

Review 2.  Therapeutics of Neurotransmitters in Alzheimer's Disease.

Authors:  Ramesh Kandimalla; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  Hyposmia may predict development of freezing of gait in Parkinson's disease.

Authors:  Jae Jung Lee; Jin Yong Hong; Jong Sam Baik
Journal:  J Neural Transm (Vienna)       Date:  2021-05-20       Impact factor: 3.575

Review 4.  Olfactory Dysfunction as an Early Biomarker in Parkinson's Disease.

Authors:  Michelle E Fullard; James F Morley; John E Duda
Journal:  Neurosci Bull       Date:  2017-08-22       Impact factor: 5.203

Review 5.  Olfaction in Parkinson's disease and related disorders.

Authors:  Richard L Doty
Journal:  Neurobiol Dis       Date:  2011-12-20       Impact factor: 5.996

6.  Sacculocolic reflex in patients with dementia: is it possible to use it for early diagnosis?

Authors:  Leman Birdane; Armagan Incesulu; Melek Kezban Gurbuz; Demet Ozbabalik
Journal:  Neurol Sci       Date:  2011-05-11       Impact factor: 3.307

7.  Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin deficits and non-motor symptoms in Parkinson's disease.

Authors:  Donald M Kuhn; Catherine E Sykes; Timothy J Geddes; Karen L Eskow Jaunarajs; Christopher Bishop
Journal:  J Neurochem       Date:  2010-12-13       Impact factor: 5.372

Review 8.  Olfactory Dysfunction in Neurodegenerative Diseases.

Authors:  Concepció Marin; Dolores Vilas; Cristóbal Langdon; Isam Alobid; Mauricio López-Chacón; Antje Haehner; Thomas Hummel; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-15       Impact factor: 4.806

9.  Does Alzheimer's disease begin in the brainstem?

Authors:  G Simic; G Stanic; M Mladinov; N Jovanov-Milosevic; I Kostovic; P R Hof
Journal:  Neuropathol Appl Neurobiol       Date:  2009-08-04       Impact factor: 8.090

10.  Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease.

Authors:  Zacharias Kohl; Nada Ben Abdallah; Jonathan Vogelgsang; Lucas Tischer; Janina Deusser; Davide Amato; Scott Anderson; Christian P Müller; Olaf Riess; Eliezer Masliah; Silke Nuber; Jürgen Winkler
Journal:  Neurobiol Dis       Date:  2015-10-30       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.